IntraOp Medical Corporation Announces Purchase of Two Next Generation Mobetrons by UCSF

SUNNYVALE, Calif.--(EON: Enhanced Online News)--IntraOp Medical Corporation (OTC:IOPD.PK) today announced that the University of California, San Francisco (UCSF) Medical Center has purchased two next generation Mobetrons for Intra-Operative Electron Radiation Therapy (IOERT). The Mobetrons will be located at the UCSF Helen Diller Family Comprehensive Cancer Center and at the Parnassus Campus of the UCSF Medical Center.

“It is only fitting that our first customer be one of the first to have our next generation machine along with Avera McKennan Hospital, and The Cleveland Clinic. I am pleased to see Mobetron delivered IOERT grow in popularity worldwide.”

UCSF Medical Center ranks among the nation’s top 10 premier hospitals for the tenth consecutive year according to the 2010-11 America’s Best Hospitals survey conducted by U.S. News & World Report. UCSF is a recognized innovator in cancer treatment, and home of the world’s first Mobetron. The Mobetron has been used to integrate IOERT into cancer treatment programs since December 1997. The Mobetron at UCSF has been treated hundreds of advanced and recurrent cancers, such as recurrent head and neck cancer, mesothelioma, recurrent rectal cancer, neuroblastoma, extremity and retroperitoneal sarcomas, and pediatric cancers.

“UCSF is committed to providing state-of-the-art, quality care to patients. IOERT focuses radiation directly where it is needed and avoids irradiating much of the healthy tissues. We look forward to making this therapy available to even more of our adult and pediatric cancer patients,” said Mack Roach, MD, chair of the UCSF Radiation Oncology Department.

IntraOp’s Mobetron is a mobile, self-shielded, technology that delivers radiation directly to a tumor site during cancer surgery without having to pass through the surrounding body structures. This procedure is called IOERT. The Mobetron enables radiation and surgical professionals to visually pinpoint the optimal site for radiation by seeing the exposed tumor bed and delivering a concentrated beam of radiation to a specific depth during cancer surgery. Clinical studies involving a number of cancer indications such as head and neck, sarcomas, colorectal, pancreatic, and breast, have shown that patients treated with IOERT often have fewer recurrences, which correlates to increased survival.

This purchase represents the 15^th and 16^th Mobetrons in the United States, and the 36^th and 37^th, worldwide. John Powers, CEO of IntraOp commented, “It is only fitting that our first customer be one of the first to have our next generation machine along with Avera McKennan Hospital, and The Cleveland Clinic. I am pleased to see Mobetron delivered IOERT grow in popularity worldwide.”

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intra-operative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, Mobetron, is the first fully portable, self-shielded intra-operative electron radiation therapy device designed for use in any operating room or office setting. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

University of California Disclaimer Statement

The information stated above was prepared by IntraOp Medical Corporation and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of IntraOp Medical Corporation, or any of its products, by The Regents of the University of California, its officers, agents and employees.